New cancer drug trial halted early – only 5 patients enrolled
NCT ID NCT04865458
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This early-stage study tested a new drug called HEC89736 in people whose B-cell blood cancers had come back or stopped responding to treatment. The main goals were to check safety, side effects, and how the body processes the drug. Only 5 people took part before the study was stopped early.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.